Integumen revenues soar as Labskin sales take off

Integumen saw revenues more than triple in its last trading year following a major restructuring project over at its Innovenn subsidiary.

The AIM-listed personal health care company witnessed revenues soar 200% to £238,000 in 2018 - primarily driven by a 480% increase in sales of its Labskin human skin equivalent.

Chief executive Gerard Brandon said: "Labskin allows skin-care, health-care, pharmaceutical manufacturers and cosmetic companies to test their products on human-like skin in a real-world environment with full access to multiple state-of-the-art partner technologies."

Integumen's order book ballooned 567% to £247,000.

The firm's male skin products wing, which reached break-even during the year, also unveiled a new formulation for its Stoer For Men skin care treatment that was being tested with CBD oils, an extract from the cannabis sativa plant.

As of 0930 GMT on Monday, Integumen shares had ticked up 0.67% to 0.60p.